Brenus Pharma has raised an €11 million Series A extension to accelerate the clinical development of its lead cancer immunotherapy and broaden its research pipeline. The financing brings the Lyon-based biotechnology company’s total capital raised since inception to €38 million, reflecting continued investor support as its lead program advances through early-stage clinical testing. The extension also expands Brenus Pharma’s international shareholder base by adding new life sciences investors from Europe and the Asia-Pacific region.
International Investor Base Expands
The financing attracted Sambrinvest, which strengthens the company’s European investor group, and Korea Omega Investment Corp., Brenus Pharma’s first institutional backer from the Asia-Pacific region. Existing shareholders also participated, including Angelor, UI Investissement through the Fonds Régional Avenir Industrie, Crédit Agricole entities CACE Création and CACF Capital Innovation, Noshaq, Orsa, BIO JAG, and Bpifrance through non-dilutive support. Their renewed commitments indicate confidence in the company’s execution across clinical, regulatory, and business development milestones.
Funding Supports STC-1010 Development
Brenus Pharma plans to use the new capital to complete the Phase I program for STC-1010 and advance a second drug candidate generated through its proprietary platform. STC-1010 is being evaluated as an in vivo, off-the-shelf immunotherapy for microsatellite-stable metastatic colorectal cancer, a form of the disease that generally responds poorly to existing immunotherapies. By financing both clinical execution and pipeline expansion, the company is seeking to reduce its dependence on a single asset while building a broader immuno-oncology portfolio.
Clinical and Regulatory Progress
The extension follows several development milestones that have lowered some of the operational and regulatory risks surrounding STC-1010. Brenus Pharma began dosing patients in its first-in-human BreAK-CRC001 study in 2025 and subsequently reported favorable early tolerability and signs of immune engagement in patients with advanced colorectal cancer. In May 2026, the US Food and Drug Administration accepted the company’s Investigational New Drug application, enabling the program’s clinical evaluation in the United States alongside European development activities.
Technology Targets Tumor Evolution
Brenus Pharma’s platform is designed to expose a broad representation of tumor-associated proteins to the immune system, with the goal of generating a multispecific response that can adapt as tumors evolve. The company describes its approach as an in vivo immunotherapy platform that mimics tumor protein expression and makes malignant cells more visible to immune defenses. This strategy is intended for difficult-to-treat solid tumors where conventional immunotherapies often produce limited responses or lose effectiveness as the disease changes.
Management and Investor Perspective
Chief Executive Officer Paul Bravetti said the extension will help Brenus Pharma finish the Phase I program and continue accelerating the platform through its next candidate. Dae Kyeong Bae, senior vice president at Korea Omega Investment, highlighted the company’s differentiated technology, early clinical validation, and pace of execution as factors supporting the investment. The participation of both returning and first-time investors provides Brenus Pharma with additional financial resources while extending its relationships across major international life sciences markets.
Strategic Significance
The transaction arrives at a critical stage for Brenus Pharma as it shifts from early clinical validation toward a more international development strategy. Additional capital should support patient recruitment, data generation, regulatory preparation, and manufacturing activities required to move STC-1010 toward later-stage studies. It also gives the company greater flexibility to develop another program from the same platform, potentially demonstrating that its technology can support multiple therapeutic assets rather than a single colorectal cancer candidate.
Brenus Pharma’s €11 million Series A extension strengthens its balance sheet and adds international investors as the company advances STC-1010 through clinical development. The round brings total funding to €38 million and supports both completion of the lead program’s Phase I work and progression of a second candidate. Future clinical results will determine whether the platform’s early promise can translate into meaningful benefits for patients with cancers that remain difficult to treat.